Identifying mRNA targets of microRNA dysregulated in cancer: With application to clear cell Renal Cell Carcinoma

BMC Systems Biology

Volumn 4, Issue , 2010, Pages

  Liu, Huiqing ^a,i   Brannon, Angela R ^b   Reddy, Anupama R ^a   Alexe, Gabriela ^c   Seiler, Michael W ^a   Arreola, Alexandra ^b   Oza, Jay H ^d   Yao, Ming ^d   Juan, David ^e   Liou, Louis S ^e,f   Ganesan, Shridar ^d   Levine, Arnold J ^g   Rathmell, W K ^b,h   Bhanot, Gyan V ^a,d,g  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CAMBRIDGE HEALTH ALLIANCE   (United States)

^g INSTITUTE FOR ADVANCED STUDY   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANIS FAMILIARIS; RATTUS;

COMPLEMENTARY DNA; MESSENGER RNA; MICRORNA; SEMA6A PROTEIN, HUMAN; SEMAPHORIN;

ANOXIA; ARTICLE; BIOLOGICAL MODEL; COHORT ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; LABORATORY DIAGNOSIS; METABOLISM; TISSUE DISTRIBUTION;

ANOXIA; CARCINOMA, RENAL CELL; COHORT STUDIES; DNA, COMPLEMENTARY; FALSE POSITIVE REACTIONS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MICRORNAS; MODELS, BIOLOGICAL; RNA, MESSENGER; SEMAPHORINS; TISSUE DISTRIBUTION;

EID: 77953677658     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/1752-0509-4-51     Document Type: Article

References (90)

1. Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet 2007, 8:93-103. 10.1038/nrg1990, 17230196.
2. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004, 5(7):522-531. 10.1038/nrg1379, 15211354.
3. Kim NV. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005, 6:376-385. 10.1038/nrm1644, 15852042.
4. Pillai RS. MicroRNA function: multiple mechanisms for a tiny RNA?. RNA 2005, 11(12):1753-1761. 10.1261/rna.2248605, 1370863, 16314451.
5. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6(11):857-866. 10.1038/nrc1997, 17060945.
6. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006, 103(7):2257-2261. 10.1073/pnas.0510565103, 1413718, 16461460.
7. Esquela-Kerscher ASlack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Can 2006, 6:259-269.
8. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA, Hannon GJ. A microRNA component of the p53 tumour suppressor network. Nature 2007, 447(7148):1130-1134. 10.1038/nature05939, 17554337.
9. Deng S, Calin GA, Croce CM, Coukos G, Zhang L. Mechanisms of microRNA deregulation in human cancer. Cell Cycle 2008, 7:2643-2646.
10. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838. 10.1038/nature03702, 15944708.
11. Barad O, Meiri E, Avniel A, Aharonov R, Barzilai A, Bentwich I, Einav U, Gilad S, Hurban P, Karov Y, Lobenhofer EK, Sharon E, Shiboleth YM, Shtutman M, Bentwich Z, Einat P. MicroRNA expression detected by oligonucleotide microarrays: system establishment and expression profiling in human tissues. Genome Res 2004, 14:2486-2494. 10.1101/gr.2845604, 534673, 15574827.
12. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, Gomella LG, Croce CM, Baffa R. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 2007, 25(5):387-392.
13. Huang Y, Dai Y, Yang J, Chen T, Yin Y, Tang M, Hu C, Zhang L. Microarray analysis of microRNA expression in renal clear cell carcinoma. Eur J Surg Oncol 2009, 35(10):1119-1123.
14. Jung M, Mollenkopf HJ, Grimm C, Wagner I, Albrecht M, Waller T, Pilarsky C, Johannsen M, Stephan C, Lehrach H, Nietfeld W, Rudel T, Jung K, Kristiansen G. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med 2009, 13(9B):3918-28. 10.1111/j.1582-4934.2009.00705.x, 19228262.
15. Juan D, Alexe G, Antes T, Liu H, Madabhushi A, Delisi C, Ganesan S, Bhanot G, Liou L. MicroRNA Expression Profile in Clear-Cell Kidney Cancer. J Urology
16. Chow TF, Youssef YM, Lianidou E, Romaschin AD, Honey RJ, Stewart R, Pace KT, Yousef GM. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem 2009, 43(1-2):150-158. 10.1016/j.clinbiochem.2009.07.020, 19646430.
17. Alimov A, Kost-Alimova M, Liu J, Li C, Bergerheim U, Imreh S, Klein G, Zabarovsky ER. Combined LOH/CGH analysis proves the existence of interstitial 3p deletions in renal cell carcinoma. Oncogene 2000, 19(11):1392-1399. 10.1038/sj.onc.1203449, 10723130.
18. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004, 101(9):2999-3004. 10.1073/pnas.0307323101, 365734, 14973191.
19. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, Stephens RM, Croce CM. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008, 68(15):6162-6170. 10.1158/0008-5472.CAN-08-0144, 2597340, 18676839.
20. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007, 67:6130-6135. 10.1158/0008-5472.CAN-07-0533, 17616669.
21. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Harris AL. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008, 141(5):672-675. 10.1111/j.1365-2141.2008.07077.x, 18318758.
22. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009, 112:55-59. 10.1016/j.ygyno.2008.08.036, 18954897.
23. Ljungberg B. Prognostic markers in renal cell carcinoma. Curr Opin Urol 2007, 17(5):303-308. 10.1097/MOU.0b013e328277f180, 17762621.
24. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF, Pogribny IP. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008, 7(7):2152-2159. 10.1158/1535-7163.MCT-08-0021, 18645025.
25. Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ. P27kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 2004, 64(11):3981-3986. 10.1158/0008-5472.CAN-03-3900, 15173011.
26. Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg 2008, 12:2171-2176. 10.1007/s11605-008-0584-x, 18642050.
27. Slack FJ, Weidhaas JB. MicroRNA in cancer prognosis. N Engl J Med 2008, 359:2720-2722. 10.1056/NEJMe0808667, 19092157.
28. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR. Breast cancer metastasis suppressor 1 up-regulates miR-146, Which suppresses breast cancer metastasis. Cancer Res 2009, 69(4):1279-1283. 10.1158/0008-5472.CAN-08-3559, 2754225, 19190326.
29. Ng Enders KO, Chris LP W, SK M, Kwong A. MicroRNA as New Players for Diagnosis, Prognosis and Therapeutic Targets in Breast Cancer. J Oncology 2009, 2009:305420.
30. Barh D, Parida S, Parida BP, Viswanathan G. Let-7, miR-125, miR-205, and miR-296 are prospective therapeutic agents in breast cancer molecular medicine. Gene Ther and Mol Biol 2008, 12:189-206.
31. Iorio MV, Casalini P, Tagliabue E, Menard S, Croce CM. MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. Eur J Cancer 2008, 44:2753-2759. 10.1016/j.ejca.2008.09.037, 19022662.
32. Corney DC, Nikitin AY. MicroRNA and ovarian cancer. Histol Histopathol 2008, 23:1161-1169. 2691660, 18581287.
33. Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih Ie M, Zhang Y, Wood W, Becker KG, Morin PJ. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS ONE 2008, 3:e2436. 10.1371/journal.pone.0002436, 2410296, 18560586.
34. Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J, Benz CC. Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 2008, 27(42):5643-5647. 10.1038/onc.2008.171, 2811234, 18504431.
35. Verghese ET, AM H, V S, TA H. Small is beautiful: microRNA and breast cancer - where are we now?. J Pathol 2008, 215:214-221. 10.1002/path.2359, 18446835.
36. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65(16):7065-7070. 10.1158/0008-5472.CAN-05-1783, 16103053.
37. MicroRNA signatures in human ovarian cancer MicroRNA signatures in human ovarian cancer. Cancer Res 2007, 67(18):8699-8707. 10.1158/0008-5472.CAN-07-1936, 17875710, MicroRNA signatures in human ovarian cancer.
38. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9(3):189-198. 10.1016/j.ccr.2006.01.025, 16530703.
39. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005, 65(14):6029-6033. 10.1158/0008-5472.CAN-05-0137, 16024602.
40. Lui WO, Pourmand N, Patterson BK, Fire A. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res 2007, 67(13):6031-6043. 10.1158/0008-5472.CAN-06-0561, 17616659.
41. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, Benjamin H, Shabes N, Tabak S, Levy A, Lebanony D, Goren Y, Silberschein E, Targan N, Ben-Ari A, Gilad S. MicroRNAs accurately identify cancer tissue origin. Nature Biotech 2008, 26(4):462-469.
42. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafrè SA, Farace MG. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27kip1. J Biol Chem 2007, 282(32):23716-23724. 10.1074/jbc.M701805200, 17569667.
43. Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V, Borbone E, Petrocca F, Alder H, Croce CM, Fusco A. MicroRNAs miR-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer 2007, 14(3):791-798. 10.1677/ERC-07-0129, 17914108.
44. Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, Ménard S, Croce CM, Tagliabue E. microRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009, 69(6):2195-2200. 10.1158/0008-5472.CAN-08-2920, 19276373.
45. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J, Song E. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131(6):1109-1123. 10.1016/j.cell.2007.10.054, 18083101.
46. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, Mendell JT. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007, 26(5):745-752. 10.1016/j.molcel.2007.05.010, 1939978, 17540599.
47. Jiang J, Lee EJ, Gusev Y, Schmittgen TD. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res 2005, 33:5394-5403. 10.1093/nar/gki863, 1236977, 16192569.
48. Smalheiser NR, Torvik VI. A population-based statistical approach identifies parameters characteristic of human microRNA-mRNA interactions. BMC Bioinformatics 2004, 5:139. 10.1186/1471-2105-5-139, 523849, 15453917.
49. Enright AJ, John B, Gaul U, Tuschl T, Sander C, Marks DS. MicroRNA targets in Drosophila. Genome Biol 2003, 5(1):R1. 10.1186/gb-2003-5-1-r1, 395733, 14709173.
50. Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N. Combinatorial microRNA target predictions. Nat Genet 2005, 37(5):495-500. 10.1038/ng1536, 15806104.
51. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007, 27(1):91-105. 10.1016/j.molcel.2007.06.017, 17612493.
52. Rajewsky N. microRNA target predictions in animals. Nat Genet 2006, 38:S8-13. 10.1038/ng1798, 16736023.
53. Sethupathy P, Megraw M, Hatzigeorgiou AG. A guide through present computational approaches for the identification of mammalian microRNA targets. Nat Methods 2006, 3(11):881-886. 10.1038/nmeth954, 17060911.
54. Megraw M, Sethupathy P, Corda B, Hatzigeorgiou AG. miRGen: a database for the study of animal microRNA genomic organization and function. Nucleic Acids Res 2007, 35:D149-155. 10.1093/nar/gkl904, 1669779, 17108354.
55. Sethupathy P, Corda B, Hatzigeorgiou AG. TarBase: A comprehensive database of experimentally supported animal microRNA targets. RNA 2006, 12:192-197. 10.1261/rna.2239606, 1370898, 16373484.
56. Didiano D, Hobert O. Perfect seed pairing is not a generally reliable predictor for miRNA-target interactions. Nat Struct Mol Biol 2006, 13(9):849-851. 10.1038/nsmb1138, 16921378.
57. Smalheiser NR, Torvik VI. Complications in mammalian microRNA target prediction. Methods Mol Biol 2006, 342:115-127.
58. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med 2009, 60:167-179. 10.1146/annurev.med.59.053006.104707, 19630570.
59. Rathmell WK, Chen S. VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Rev Anticancer Ther 2008, 8(1):63-73. 10.1586/14737140.8.1.63, 18095884.
60. Calzada MJ, del Peso L. Hypoxia-inducible factors and cancer. Clin Transl Oncol 2007, 9(5):278-289. 10.1007/s12094-007-0055-y, 17525038.
61. Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med 2007, 13:223-230. 10.1016/j.molmed.2007.04.001, 2686126, 17462954.
62. Ficarra V, Martignoni G, Maffei N, Brunelli M, Novara G, Zanolla L, Pea M, Artibani W. Original and reviewed nuclear grading according to the Fuhrman system: a multivariate analysis of 388 patients with conventional renal cell carcinoma. Cancer 2005, 103:68-75. 10.1002/cncr.20749, 15573369.
63. Boer JM, Huber WK, Sültmann H, Wilmer F, von Heydebreck A, Haas S, Korn B, Gunawan B, Vente A, Füzesi L, Vingron M, Poustka A. Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res 2001, 11(11):1861-1870. 311168, 11691851.
64. Brannon AR, Reddy A, Seiler M, Arreola A, Moore DT, Pruthi RS, Wallen EM, Nielsen ME, Liu H, Ljungberg B, Zhao H, Brooks JD, Nathanson KL, Ganesan S, Bhanot G, Rathmell WK. Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes and Cancer
65. Liu H, Alexe G, Juan D, Antes T, Liou L, Ganesan S, Bhanot G. A Procedure to identify MicroRNA gene targets in human kidney cancer. Proceedings of the 12th International Conference on Research in Computational Molecular Biology (RECOMB08): Singapore 2008,
66. Petillo D, Kort EJ, Anema J, Furge KA, Yang XJ, Teh BT. MicroRNA profiling of human kidney cancer subtypes. Int J Oncol 2009, 35:109-114. 10.3892/ijo_00000318, 19513557.
67. Tamura M, Gu J, Tran H, Yamada KM. PTEN gene and integrin signaling in cancer. J Natl Cancer Inst 1999, 91(21):1820-1828. 10.1093/jnci/91.21.1820, 10547389.
68. Hara S, Oya M, Mizuno R, Horiguchi A, Marumo K, Murai M. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann Oncol 2005, 16(6):928-933. 10.1093/annonc/mdi182, 15851405.
69. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB, Stokoe D, Giaccia AJ. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000, 14(4):391-396. 316386, 10691731.
70. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O'Toole T, Gibbons J, Belldegrun AS, Figlin RA. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007, 109(11):2257-2267. 10.1002/cncr.22677, 17440983.
71. Dromard M, Bompard G, Glondu-Lassis M, Puech C, Chalbos D, Freiss G. The putative tumor suppressor gene PTPN13/PTPL1 induces apoptosis through insulin receptor substrate-1 dephosphorylation. Cancer Res 2007, 67(14):6806-6813. 10.1158/0008-5472.CAN-07-0513, 17638892.
72. Felipe A, Vicente R, Villalonga N, Roura-Ferrer M, Martínez-Mármol R, Solé L, Ferreres JC, Condom E. Potassium channels: new targets in cancer therapy. Cancer Detect Prev 2006, 30(4):375-385. 10.1016/j.cdp.2006.06.002, 16971052.
73. Yamazaki K, Sakamoto M, Ohta T, Kanai Y, Ohki M, Hirohashi S. Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene 2003, 22(6):847-52. 10.1038/sj.onc.1206153, 12584564.
74. Dutta KK, Zhong Y, Liu YT, Yamada T, Akatsuka S, Hu Q, Yoshihara M, Ohara H, Takehashi M, Shinohara T, Masutani H, Onuki J, Toyokuni S. Association of microRNA-34a overexpression with proliferation is cell type-dependent. Cancer Sci 2007, 98(12):1845-1852. 10.1111/j.1349-7006.2007.00619.x, 17888029.
75. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, Sun LZ, Ahlquist DA, Wood CG, Copland JA. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 2007, 13(16):4740-4749. 10.1158/1078-0432.CCR-07-0143, 17699851.
76. Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 2005, 11(3):1119-1128.
77. Henrich KO, Fischer M, Mertens D, Benner A, Wiedemeyer R, Brors B, Oberthuer A, Berthold F, Wei JS, Khan J, Schwab M, Westermann F. Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients. Clin Cancer Res 2006, 12(1):131-138. 10.1158/1078-0432.CCR-05-1431, 16397034.
78. Thomasson M, Hedman H, Junttila TT, Elenius K, Ljungberg B, Henriksson R. ErbB4 is downregulated in renal cell carcinoma--a quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family. Acta Oncol 2004, 43(5):453-459. 10.1080/02841860410028574, 15360049.
79. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, Harris AL, Gleadle JM, Ragoussis J. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 2008, 14(5):1340-1348. 10.1158/1078-0432.CCR-07-1755, 18316553.
80. Kulshreshtha R, Davuluri RV, Calin GA, Ivan M. A microRNA component of the hypoxic response. Cell Death Differ 2008, 15(4):667-671. 10.1038/sj.cdd.4402310, 18219318.
81. Baudis M. Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data. BMC Cancer 2007, 7:226. 10.1186/1471-2407-7-226, 2225423, 18088415.
82. Yamaguchi A, Hori O, Stern DM, Hartmann E, Ogawa S, Tohyama M. Stress-associated endoplasmic reticulum protein 1 (SERP1)/Ribosome-associated membrane protein 4 (RAMP4) stabilizes membrane proteins during stress and facilitates subsequent glycosylation. J Cell Biol 1999, 147(6):1195-1204. 10.1083/jcb.147.6.1195, 2168098, 10601334.
83. Wilhelm M, Veltman JA, Olshen AB, Jain AN, Moore DH, Presti JC, Kovacs G, Waldman FM. Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer. Cancer Res 2002, 62(4):957-960.
84. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008, 283(22):14910-14914. 10.1074/jbc.C800074200, 18411277.
85. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008, 22(7):894-907. 10.1101/gad.1640608, 2279201, 18381893.
86. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008, 9(6):582-589. 10.1038/embor.2008.74, 2396950, 18483486.
87. Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T, Nguyen LT, Hijiya N, Uchida T, Sato F, Mimata H, Seto M, Moriyama M. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol 2008, 216(4):418-427. 10.1002/path.2437, 18925646.
88. Dhanabal M, Wu F, Alvarez E, McQueeney KD, Jeffers M, MacDougall J, Boldog FL, Hackett C, Shenoy S, Khramtsov N, Weiner J, Lichenstein HS, LaRochelle WJ. Recombinant semaphorin 6A-1 ectodomain inhibits in vivo growth factor and tumor cell line-induced angiogenesis. Cancer Biol Ther 2005, 4(6):659-668.
89. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531-537. 10.1126/science.286.5439.531, 10521349.
90. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003, 100(16):9440-9445. 10.1073/pnas.1530509100, 170937, 12883005.